Severe Hypertrophic Cardiomyopathy Caused by a Protein Kinase Adenosine Monophosphate-Activated Non-catalytic Subunit Gamma 2 (PRKAG2) Mutation With Refractory Chylous Effusions in a Neonate: A Case Report and Literature Review

新生儿难治性乳糜胸合并蛋白激酶腺苷单磷酸激活非催化亚基γ2 (PRKAG2) 基因突变引起的严重肥厚型心肌病:病例报告及文献复习

阅读:1

Abstract

Protein kinase adenosine monophosphate-activated non-catalytic subunit gamma 2 (PRKAG2) cardiac syndrome is a rare genetic disorder characterized by hypertrophic cardiomyopathy and heart rhythm disturbances caused by mutations in the PRKAG2 gene. Reports on PRKAG2 cardiac syndrome associated with refractory chylous effusion are extremely limited. Here, we present a neonatal case involving severe hypertrophic obstructive cardiomyopathy accompanied by chylous ascites and lymphatic malformations. The patient was diagnosed prenatally with hypertrophic cardiomyopathy. After birth, she developed severe respiratory failure, along with refractory chylous and pericardial effusions. Lymphoscintigraphy revealed lymphatic malformations in the right inguinal region. Prednisolone and sirolimus were administered to manage the chylous ascites and lymphatic malformations. Unfortunately, the patient succumbed to sepsis at two months of age. A de novo c.1592G>A (p.Arg531Gln) heterozygous variant of PRKAG2 has also been identified. The association between PRKAG2, chylous effusion, and lymphatic malformations remains unclear. Further research is required to assess the effects and safety of prednisolone and sirolimus on chylous ascites in patients with PRKAG2 cardiac syndrome.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。